ForbesPro
Benign Prostatic Hyperplasia (BPH) is not merely a medical diagnosis; for millions of men worldwide, it exacts a heavy toll on their quality of life. While the field has evolved from major surgeries to minimally invasive procedures, a stubborn constraint remains: the standard of care still relies on invasive entry through the urethra.
NINA Medical extends this trend, taking the leap from minimally invasive to completely non-invasive care. This represents a major advancement and a vital solution for the many men who currently reject transurethral procedures. NINA’s vision is to fundamentally change this paradigm, offering an alternative that is friendly to both patients and healthcare systems.
From Vision to Clinical Reality
A major vote of confidence in the company’s potential arrived with the successful completion of a funding round led by a prominent U.S.-based venture capital firm. This capital drove the transition from development to execution, allowing the company to strengthen its management team with veteran executives and launch its clinical program.
Powered by this support, NINA achieved an unprecedented global milestone: initiating clinical studies at Rambam Health Care Campus in Haifa and Assuta Medical Center in Tel Aviv. These trials represent a world first—the inaugural application of a completely non-invasive treatment for an enlarged prostate.
The Science of Precision
While the use of High-Intensity Focused Ultrasound (HIFU) for thermal ablation of the prostate has already been clinically proven in products using a transrectal probe for prostate cancer, NINA Medical has developed a different approach. The company uses the perineum as an access point to the pelvic floor, employing proprietary technology it developed for HIFU beam visualization and focal-point tracking.
This visibility unlocks a geometric advantage. Because the system tracks the beam with such precision, it can treat the prostate from the perineum (the area between the scrotum and the anus). This “long-range” approach completely bypasses the urethra and rectum, ensuring a level of safety and dignity previously unseen in the field. This unique method is protected by a global patent portfolio approved in the U.S., Europe, and China.
Leading the Charge
To translate this technological edge into market reality, NINA Medical has recruited one of the most experienced voices in the field.
John Linn, President, U.S. Operations
In November, John Linn joined NINA Medical to spearhead its U.S. expansion. An industry veteran with 21 years of experience, Linn is synonymous with the commercial success of High-Intensity Focused Ultrasound (HIFU) in urology. As the former Founder and CEO of HIFU Prostate Services, which he successfully exited in 2025, Linn has guided the technology through every critical phase—from early clinical trials and FDA clearance to building a scalable commercial infrastructure.
“NINA’s BPH solution will be welcomed by patients, physicians, and facilities alike,” says Linn. “It is a true game-changer in the management of BPH.”
Dr. Howard Goldman, Scientific Advisor
The company’s clinical vision is further bolstered by Dr. Howard Goldman, a senior urologist at Cleveland Clinic and a scientific advisor to the company. “As urologists, we face a daily challenge: offering effective treatment without compromising a man’s quality of life,” explains Dr. Goldman. “NINA Medical’s use of focused ultrasound through the perineum represents a true paradigm shift. The ability to treat the prostate accurately and non-invasively, while circumventing the complications of existing treatments, holds the potential to become the future standard of care for millions of men worldwide.”
Strategic Expansion
NINA Medical is now gearing up for significant expansion in 2026, with a central goal of launching clinical trials at leading U.S. sites. The company anticipates a streamlined FDA regulatory pathway, leveraging existing HIFU precedents and the relatively rapid relief of BPH symptoms. In a market where major acquisitions have recently underscored a hunger for less invasive innovation, NINA is well positioned to meet the demand for patient-centric care.
ForbesPro is Forbes Israel’s Paid Promotional Content Brand
